Clinical Trial Update: Study to Assess the Impact on Calcium Levels When Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT) Switch From Cinacalcet to Etelcalcetide [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the impact on calcium levels when hemodialysis patients with secondary hyperparathyroidism switch from cinacalcet to etelcalcetide. Th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism Secondary

Drugs mentioned

• Etelcalcetide (etelcalcetide)
• cinacalcet (cinacalcet hydrochloride)

Snippet

Sponsor: Amgen | Conditions: Hyperparathyroidism, Secondary | Phase 3 | Status: COMPLETED | Results posted: 2017-04-04